150 related articles for article (PubMed ID: 32816071)
1. [Successful treatment of adult Still's disease with tofacitinib in a HIV-2 positive female patient].
Hoff P; Walther M; Wesselmann H; Weinerth J; Feist E; Ohrndorf S
Z Rheumatol; 2020 Dec; 79(10):1046-1049. PubMed ID: 32816071
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome.
Honda M; Moriyama M; Kondo M; Kumakura S; Murakawa Y
Scand J Rheumatol; 2020 Jul; 49(4):336-338. PubMed ID: 32329389
[No Abstract] [Full Text] [Related]
3. Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.
Hu Q; Wang M; Jia J; Teng J; Chi H; Liu T; Liu HL; Cheng X; Ye J; Su Y; Sun Y; Zhou Z; Wan L; Wang Z; Wang F; Shi H; Yang C
Ann Rheum Dis; 2020 Jun; 79(6):842-844. PubMed ID: 32079571
[No Abstract] [Full Text] [Related]
4. Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia.
Nagasaki Y; Miyamoto T; Henzan H; Nagafuji K; Harada M; Akashi K
J Rheumatol; 2009 Jun; 36(6):1349-51. PubMed ID: 19509096
[No Abstract] [Full Text] [Related]
5. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease.
Banse C; Vittecoq O; Benhamou Y; Gauthier-Prieur M; Lequerré T; Lévesque H
Joint Bone Spine; 2013 Dec; 80(6):653-5. PubMed ID: 23751410
[TBL] [Abstract][Full Text] [Related]
6. Adult-onset Still's disease in a patient with cystic fibrosis and its successful treatment with anakinra.
Albersmeyer MP; Hilge RG; Schulze-Koops H; Sitter T
Rheumatology (Oxford); 2012 Sep; 51(9):1730-2. PubMed ID: 22513144
[No Abstract] [Full Text] [Related]
7. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
Lenert A; Yao Q
Semin Arthritis Rheum; 2016 Jun; 45(6):711-6. PubMed ID: 26672682
[TBL] [Abstract][Full Text] [Related]
8. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
10. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
11. Liver failure in adult Still's disease during corticosteroid treatment.
Ott SJ; Baron A; Berghaus T; Lamerz R; Beuers U
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):87-90. PubMed ID: 12544700
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
13. Adult-onset Still's disease with disseminated intravascular coagulation and hemophagocytic syndrome: a case report.
Mimura T; Shimodaira M; Kibata M; Tsukadaira A; Shirahata K
BMC Res Notes; 2014 Dec; 7():940. PubMed ID: 25532568
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
[TBL] [Abstract][Full Text] [Related]
15. Cardiac magnetic resonance in myocarditis from adult onset Still's disease successfully treated with anakinra.
Choi AD; Moles V; Fuisz A; Weissman G
Int J Cardiol; 2014; 172(1):e225-7. PubMed ID: 24461482
[No Abstract] [Full Text] [Related]
16. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
Erduran F; Adışen E; Aksakal AB
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
18. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
[TBL] [Abstract][Full Text] [Related]
19. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Charles-Schoeman C; DeMasi R; Valdez H; Soma K; Hwang LJ; Boy MG; Biswas P; McInnes IB
Arthritis Rheumatol; 2019 Sep; 71(9):1450-1459. PubMed ID: 31385441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
